Quadrant Capital Group’s Mineralys Therapeutics MLYS Stock Holding History

Quadrant Capital Group’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$136	Sell	5 -3	-38%	-$88	﹤0.01%	2683
2025 Q4	$291	Sell	8 -2	-20%	-$80	﹤0.01%	2675
2025 Q3	$380	Buy	+10	New	+$216	﹤0.01%	2631
2025 Q2	–	Sell	-112	Closed	-$1.78K	–	2101
2025 Q1	$1.78K	Sell	112 -17	-13%	-$196	﹤0.01%	2528
2024 Q4	$1.59K	Hold	129	–	–	﹤0.01%	2527
2024 Q3	$1.56K	Hold	129	–	–	﹤0.01%	2528
2024 Q2	$1.51K	Hold	129	–	–	﹤0.01%	2514
2024 Q1	$1.67K	Hold	129	–	–	﹤0.01%	2534
2023 Q4	$1.11K	Buy	+129	New	+$1.01K	﹤0.01%	2546

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Quadrant Capital Group's MLYS Position: Q1 2026 in Review

Quadrant Capital Group reduced its Mineralys Therapeutics (MLYS) stake by 38% in Q1 2026, selling an estimated $88 and leaving 5 shares worth $136. The position accounts for ﹤0.01% of the portfolio, ranked #2683.

Quadrant Capital Group first reported a position in MLYS in Q4 2023 and has held it in 9 quarters since. The position peaked at $1.78K in Q1 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

Quadrant Capital Group held 5 shares of Mineralys Therapeutics worth $136 as of Q1 2026.
Quadrant Capital Group sold 3 Mineralys Therapeutics shares in Q1 2026, an estimated $88.
Mineralys Therapeutics made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2683 holding.
Quadrant Capital Group first reported a position in Mineralys Therapeutics in Q4 2023 and has held it in 9 quarters since.
Quadrant Capital Group's Mineralys Therapeutics position peaked at $1.78K in Q1 2025.
214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.